Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Allogeneic stem cell transplantation].

K Sawafuji1, S Okamoto

  • 1Division of Hematology, Department of Internal Medicine, Keio University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to combined modality treatment in a five-year survivor of extensive small cell lung cancer with severe complications.

Internal medicine (Tokyo, Japan)·2000
Same author

Itraconazole and retinoid resistance.

American journal of hematology·1995
Same author

Serum 7 alpha-hydroxycholesterol as a new parameter of liver function in patients with chronic liver diseases.

Hepatology (Baltimore, Md.)·1995
Same author

Placement of the urethral stent made of shape memory alloy in management of benign prostatic hypertrophy for debilitated patients.

The Journal of urology·1995
Same author

Design of noncovalent trypsin inhibitor based on the X-ray crystal structure of the complex.

Biochemical and biophysical research communications·1995
Same author

Application of a unique automated synthesis system for solution-phase peptide synthesis.

Chemical & pharmaceutical bulletin·1995

Four main treatments, including stem cell transplants and tyrosine kinase inhibitors, have improved chronic myelogenous leukemia (CML) outcomes. This review compares transplantation and donor lymphocyte infusions with other CML therapies.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Context:

  • Chronic myelogenous leukemia (CML) prognosis has significantly improved over the past 20 years.
  • Four primary therapeutic strategies have emerged, each targeting distinct CML biology.
  • These include allogeneic stem cell transplantation, interferon-alpha regimens, donor lymphocyte infusions, and BCR/ABL tyrosine kinase inhibitors.

Purpose:

  • To provide an updated comparison of different therapeutic modalities for CML.
  • To evaluate the efficacy and risk-benefit ratios of various CML treatments.
  • To analyze the outcomes of related and unrelated donor transplantation, donor lymphocyte infusions, and non-myeloablative stem cell transplantation in CML.

Summary:

  • This review updates the results of allogeneic stem cell transplantation (SCT) and donor lymphocyte infusions (DLI) in CML.

Related Experiment Videos

  • It compares these approaches with other established CML treatments, including interferon-alpha and tyrosine kinase inhibitors (TKIs).
  • The analysis focuses on related and unrelated donor SCT, DLI, and non-myeloablative SCT, assessing their comparative effectiveness.

    • Impact:

    • This comparative analysis aids in understanding the evolving landscape of CML treatment.
    • It provides crucial data for clinicians in selecting optimal therapeutic strategies for CML patients.
    • The findings contribute to refining risk-benefit assessments for various CML interventions, potentially improving patient survival and quality of life.